Vemurafenib Clinical Trials

7 actively recruiting trials across 3 locations

Also known as: BRAF (V600E) kinase inhibitor RO5185426, BRAF(V600E) Kinase Inhibitor RO5185426, PLX-4032, PLX4032, RG 7204, RG7204, RO 5185426, Vemurafenib branded as Zelboraf, Zelboraf

Filter by location:

Other3 trials

DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

Phase 2/3

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

Phase 2

Duarte, California2 trials

A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

City of Hope Comprehensive Cancer Center

Phase 2

Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation

City of Hope Medical Center

Phase 2

Louisville, Kentucky1 trial

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients

James Graham Brown Cancer Center-University of Louisville

Phase 1/2

Boston, Massachusetts1 trial

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Dana Farber Cancer Institute

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.